Potent, Long-Acting Cyclopentane-1,3-Dione Thromboxane (A2)-Receptor Antagonists

被引:5
作者
Wang, Xiaozhao [1 ]
Liu, Li [2 ]
Huang, Longchuan [1 ]
Herbst-Robinson, Katie [2 ]
Cornec, Anne-Sophie [1 ]
James, Michael J. [2 ]
Sugiyama, Shimpei [1 ]
Bassetto, Marcella [2 ]
Brancale, Andrea [2 ]
Trojanowski, John Q. [2 ]
Lee, Virginia M. -Y. [2 ]
Smith, Amos B., III [1 ]
Brunden, Kurt R. [2 ]
Ballatore, Carlo [1 ,2 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Chem, Sch Arts & Sci, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2014年 / 5卷 / 09期
关键词
Cyclopentane-1,3-dione; carboxylic acid bioisostere; thromboxane A2; thromboxane receptor antagonists; RECEPTOR ANTAGONISTS; TETRAHYDRONAPHTHALENE DERIVATIVES; TERUTROBAN; DISEASE; PERFORM; BIOLOGY; BINDING; EVENTS; DESIGN; STROKE;
D O I
10.1021/ml5002085
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of derivatives of the known thromboxane A(2) prostanoid (TP) receptor antagonists, 3-(6-((4-chlorophenyl)sulfonamido)-5,6,7,8-tetrahydronaphthalen-1-yl)propanoic acid and 3-(3-(2-((4-chlorophenyl)sulfonamido)ethyl)phenyl) propanoic acid, were synthesized in which the carboxylic acid functional group was replaced with substituted cyclopentane-1,3-dione (CPD) bioisosteres. Characterization of these molecules led to the discovery of remarkably potent new analogues, some of which were considerably more active than the corresponding parent carboxylic acid compounds. Depending on the choice of the C2 substituent of the CPD unit, these new derivatives can produce either a reversible or an apparent irreversible inhibition of the human TP receptor. Given the potency and the long-lasting inhibition of TP receptor signaling, these novel antagonists may comprise promising leads for the development of antithromboxane therapies.
引用
收藏
页码:1015 / 1020
页数:6
相关论文
共 22 条
[1]   Cyclopentane-1,3-dione: A Novel Isostere for the Carboxylic Acid Functional Group. Application to tie Design of Potent Thromboxane (A2) Receptor Antagonists [J].
Ballatore, Carlo ;
Soper, James H. ;
Piscitelli, Francesco ;
James, Michael ;
Huang, Longchuan ;
Atasoylu, Onur ;
Huryn, Donna M. ;
Trojanowski, John Q. ;
Lee, Virginia M. -Y. ;
Brunden, Kurt R. ;
Smith, Amos B., III .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (19) :6969-6983
[2]   The Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study: Baseline Characteristics of the Population [J].
Bousser, M. G. ;
Amarenco, P. ;
Chamorro, A. ;
Fisher, M. ;
Ford, I. ;
Fox, K. ;
Hennerici, M. ;
Mattle, H. P. ;
Rothwell, P. M. .
CEREBROVASCULAR DISEASES, 2009, 27 (06) :608-613
[3]   New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors [J].
Cimetière, B ;
Dubuffet, T ;
Landras, C ;
Descombes, JJ ;
Simonet, S ;
Verbeuren, TJ ;
Lavielle, G .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (11) :1381-1386
[4]   Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists [J].
Cimetière, B ;
Dubuffet, T ;
Muller, O ;
Descombes, JJ ;
Simonet, S ;
Laubie, M ;
Verbeuren, TJ ;
Lavielle, J .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (11) :1375-1380
[5]   Thromboxane modulating agents .3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists [J].
Dickinson, RP ;
Dack, KN ;
Long, CJ ;
Stelle, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (21) :3442-3452
[6]   From the design to the clinical application of thromboxane modulators [J].
Dogné, JM ;
Hanson, J ;
de Leval, X ;
Pratico, D ;
Pace-Asciak, CR ;
Drion, P ;
Pirotte, B ;
Ruan, KH .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (08) :903-923
[7]   Cation-pi interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp [J].
Dougherty, DA .
SCIENCE, 1996, 271 (5246) :163-168
[8]   The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis [J].
Ekambaram, Prasanna ;
Lambiv, Wanyu ;
Cazzolli, Rosanna ;
Ashton, Anthony W. ;
Honn, Kenneth V. .
CANCER AND METASTASIS REVIEWS, 2011, 30 (3-4) :397-408
[9]   THROMBOXANES - NEW GROUP OF BIOLOGICALLY-ACTIVE COMPOUNDS DERIVED FROM PROSTAGLANDIN ENDOPEROXIDES [J].
HAMBERG, M ;
SVENSSON, J ;
SAMUELSSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (08) :2994-2998
[10]  
HIRAGA K, 1965, CHEM PHARM BULL, V13, P1300